The liquid hospital, a new patient care model based on e-health, represents a paradigm shift towards more personalized and precise medicine. The challenge in this context is cybersecurity in the interconnection between systems and medical devices inside and outside healthcare centers, as well as ensuring people's privacy

In silico research entails modeling, simulating, and visualizing biological and medical processes using computers. This context requires more collaborative research and data sharing for training mathematical models. Federated networks become a key element in ensuring the secure use of data

According to the IADB's cybersecurity guide for the healthcare sector, there is an average period of 329 days from a successful cyberattack to the institution’s awareness of its data breach

Cybersecurity incident response centers must possess advanced automation systems powered by artificial intelligence models. They need technology that can enhance the organization’s visibility when handling potential security incidents, along with response teams whose work is uniform and traceable

Analyzing speech can prove to be a valuable tool in predicting the onset of Alzheimer’s disease, according to research conducted using artificial intelligence tools in the TARTAGLIA project

Certain aspects of spontaneous language are linked to patients who exhibit an accumulation of beta-amyloid protein in the brain, a defining characteristic of individuals with this form of dementia

The technological development of MedP-Big Data project is complete. This project aims to improve personalized patient care, health promotion, prevention, and treatment using big data and artificial intelligence (AI)

The project will enable the healthcare services in the Canary Islands and Valencia to promote personalized and precision medicine

This is an example of a national project whose use cases could be applied to any current healthcare service

It is the second most common type of cancer that affects more than 1.2 million men worldwide and is the third leading cause of cancer death

With its technology, GMV facilitates the application of evidence-based personalized medicine, as well as the development of clinical guidelines for the benefit of the patient

Together with PIONEER and OPTIMA, the Evidence Hub of the European Association of Urology (EAU) and TARTAGLIA are some examples of GMV's contribution to the fight against prostate cancer